IFNGR1
IFNGR1 (Interferon gamma receptor 1) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Melanoma.
Overview
Receptor subunit for interferon gamma/INFG that plays crucial roles in antimicrobial, antiviral, and antitumor responses by activating effector immune cells and enhancing antigen presentation. Associates with transmembrane accessory factor IFNGR2 to form a functional receptor. Upon ligand binding, the intracellular domain of IFNGR1 opens out to allow association of downstream signalling components JAK1 and JAK2.
CIViC holds 1 clinical evidence item and 0 assertions across 2 variants, naming Ipilimumab.
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · IFNGR1 (Interferon gamma receptor 1) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Melanoma.
- 1 · What it is
IFNGR1 (Interferon gamma receptor 1) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Melanoma.
- 2 · What goes wrong in cancer
Receptor subunit for interferon gamma/INFG that plays crucial roles in antimicrobial, antiviral, and antitumor responses by activating effector immune cells and enhancing antigen presentation.
- 3 · How drugs use it
No product in this corpus aims at IFNGR1 yet. Drugs bind the molecule precisely: to switch it off, flag the cell for the immune system, or deliver a payload.
External identifiers
Sources: HGNC HGNC:5439 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt P15260 (protein name, function text, keywords and locations (REST API)); CIViC gene IFNGR1 (1 evidence items, 0 assertions, 2 variants; diseases: Melanoma (GraphQL API, CC0))
Biology
Receptor subunit for interferon gamma/INFG that plays crucial roles in antimicrobial, antiviral, and antitumor responses by activating effector immune cells and enhancing antigen presentation. Associates with transmembrane accessory factor IFNGR2 to form a functional receptor. Upon ligand binding, the intracellular domain of IFNGR1 opens out to allow association of downstream signalling components JAK1 and JAK2. In turn, activated JAK1 phosphorylates IFNGR1 to form a docking site for STAT1. Subsequent phosphorylation of STAT1 leads to dimerisation, translocation to the nucleus, and stimulation of target gene transcription. STAT3 can also be activated in a similar manner although activation seems weaker. Location: Cell membrane (UniProt). Locus 6q23.3 (HGNC).
- Melanoma: CIViC evidence names this disease
Notes
top- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: CIViC lists 1 therapies; CIViC holds 1 clinical evidence items on its variants. Evidence tier "clinical-evidence" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.
Latest papers
topQuery for this target: (TITLE:"IFNGR1" OR ABSTRACT:"IFNGR1" OR TITLE:"interferon gamma receptor 1" OR ABSTRACT:"interferon gamma receptor 1" OR TITLE:"Interferon gamma receptor 1" OR ABSTRACT:"Interferon gamma receptor 1" OR TITLE:"CD119" OR ABSTRACT:"CD119" OR TITLE:"IFNGR" OR ABSTRACT:"IFNGR") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about IFNGR1, not a curated reading list.